Introducing Proven Connect, a new translational programme for PCR
Prostate Cancer Research has announced a new programme of work that will deliver on the charity’s commitment to support and accelerate translational research. Proven Connect will work to improve access to seed funding, expertise and networks and to build collaborations and partnerships in the translational research space.
Article Information
Date: February 28, 2022

Share this

Born of 30 years' experience in funding academic prostate cancer research, Proven Connect will support a portfolio of promising companies that could impact prostate cancer treatment and diagnosis for the benefit of patients.

Through Proven Connect, PCR will co-invest with venture capital funders and impact investors and connect companies to the resources and expert support they need to succeed.  [This programme is already supporting the delivery of breakthroughs, with funding for Cambridge spin-out Lucida Medical supporting the development of its machine learning software for prostate cancer detection from MRI.] PCR aims to generate a substantial increase in equity funding for early-stage companies that are working on treatments, diagnostics and services that tackle prostate cancer.”

Matthew Ellis, Chair of PCR said “In creating Proven Connect, we’re fostering an environment that will support and accelerate the development of patient-centric prostate cancer innovation through to the clinic. Combining investment with strategic partnerships will help those diagnosed with prostate cancer to live longer and with a better quality of life.”

Oliver Kemp, Chief Executive of PCR said “Too many promising innovations fail to make the leap into the clinic. It’s incredibly important that we continue to support new approaches to the diagnosis, care and treatment of prostate cancer patients right through to patients in the clinic.”

Jayne Spink, Translational Research Director for PCR and Director of Proven Connect] said “ Proven Connect’s offering is unique. We see massive potential emerging from early stage research and its so important that innovators are supported to overcome barriers to translation. Proven Connect is about facilitating access to finance and expertise at the start of the journey; but it’s also about helping to generate strategic relationships and maintaining momentum.”

Proven Connect will operate a model of strategic collaboration. Investors, innovators and professionals working in the field of prostate cancer research and care are invited to explore opportunities to work with Proven Connect [provenconnect.com, info@provenconnect.com]